Xintela (XINT) investor relations material

Company overview and platform

• Focuses on developing and commercializing stem cell therapies, with a lead product, Xtamp, targeting osteoarthritis and other indications through partnering and licensing.

• Operates with a team of about 15 people, listed on NASDAQ First North, and has a major shareholder, Ferri.

• Utilizes a proprietary selection technology for mesenchymal stem cells (MSCs), ensuring high purity and potency by targeting integrin alpha-ten beta-one.

• In-house GMP facility provides manufacturing control, flexibility, cost reduction, and generates revenue through services to other cell therapy developers.

Clinical study results and product differentiation

• Completed a Phase IIIa clinical study in osteoarthritis, showing Xtamp is safe and well tolerated at all dose levels, with no adverse events.

• Highest dose demonstrated no change in joint space, indicating a halt in cartilage degradation, and showed reduction in bone marrow lesions and improved bone structure.

• Significant pain reduction and improved knee function observed within one month, lasting up to two years post-treatment.

• Results support disease-modifying potential, with best therapeutic effects at the highest dose.

Preclinical and additional indications

• Preclinical studies in horses and rabbits confirmed safety, efficacy, and mechanism of action, with MSCs homing to damaged tissue and differentiating into cartilage cells.

• Xtamp platform is being explored for difficult-to-heal wounds, acute respiratory distress syndrome, and other musculoskeletal and skin diseases.

• Product patents granted for all therapeutic uses of Xtamp.